CN108066647B - Traditional Chinese medicine composition for delaying diabetes cognitive dysfunction and preparation method thereof - Google Patents
Traditional Chinese medicine composition for delaying diabetes cognitive dysfunction and preparation method thereof Download PDFInfo
- Publication number
- CN108066647B CN108066647B CN201810004308.1A CN201810004308A CN108066647B CN 108066647 B CN108066647 B CN 108066647B CN 201810004308 A CN201810004308 A CN 201810004308A CN 108066647 B CN108066647 B CN 108066647B
- Authority
- CN
- China
- Prior art keywords
- water
- plaque
- extract
- pill
- pills
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 31
- 208000010877 cognitive disease Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title claims description 7
- 241001289529 Fallopia multiflora Species 0.000 claims abstract description 9
- 241000545744 Hirudinea Species 0.000 claims abstract description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 5
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 5
- 235000008434 ginseng Nutrition 0.000 claims abstract description 5
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 4
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 4
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 4
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 52
- 239000006187 pill Substances 0.000 claims description 46
- 239000000843 powder Substances 0.000 claims description 30
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 18
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 18
- 241001330002 Bambuseae Species 0.000 claims description 18
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 18
- 239000011425 bamboo Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 13
- 239000008188 pellet Substances 0.000 claims description 11
- 230000001680 brushing effect Effects 0.000 claims description 9
- 238000007598 dipping method Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000005096 rolling process Methods 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- 238000000465 moulding Methods 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 102000007625 Hirudins Human genes 0.000 claims description 3
- 108010007267 Hirudins Proteins 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 239000010419 fine particle Substances 0.000 claims description 3
- 229940089161 ginsenoside Drugs 0.000 claims description 3
- 229930182494 ginsenoside Natural products 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 3
- 229940006607 hirudin Drugs 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 235000012149 noodles Nutrition 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 3
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims 1
- 241001061264 Astragalus Species 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims 1
- 235000006533 astragalus Nutrition 0.000 claims 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims 1
- 210000004233 talus Anatomy 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004556 brain Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 241000208340 Araliaceae Species 0.000 abstract description 4
- 208000020358 Learning disease Diseases 0.000 abstract description 4
- 244000241838 Lycium barbarum Species 0.000 abstract description 4
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 4
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 4
- 208000026139 Memory disease Diseases 0.000 abstract description 4
- 235000019206 astragalus extract Nutrition 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 239000002389 essential drug Substances 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 235000020710 ginseng extract Nutrition 0.000 abstract description 4
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 201000003723 learning disability Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 208000000044 Amnesia Diseases 0.000 abstract description 2
- 208000031091 Amnestic disease Diseases 0.000 abstract description 2
- 102000016938 Catalase Human genes 0.000 abstract description 2
- 108010053835 Catalase Proteins 0.000 abstract description 2
- 206010012289 Dementia Diseases 0.000 abstract description 2
- -1 Lipid Peroxide Chemical class 0.000 abstract description 2
- 208000036626 Mental retardation Diseases 0.000 abstract description 2
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 2
- 241000209140 Triticum Species 0.000 abstract description 2
- 235000021307 Triticum Nutrition 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000006986 amnesia Effects 0.000 abstract description 2
- 229940107666 astragalus root Drugs 0.000 abstract description 2
- 230000002950 deficient Effects 0.000 abstract description 2
- 229940107131 ginseng root Drugs 0.000 abstract description 2
- 239000010977 jade Substances 0.000 abstract description 2
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 230000008897 memory decline Effects 0.000 abstract description 2
- 230000003340 mental effect Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 41
- 238000002474 experimental method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000007087 memory ability Effects 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical group O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000036544 posture Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001604597 Pyrestini Species 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a health care product for delaying cognitive dysfunction of diabetes, which comprises the following components: ginseng extract, astragalus extract, polygonum multiflorum extract, medlar extract, hordei yumai beard extract and leech extract. The cognitive dysfunction of diabetes belongs to the category of dementia in traditional Chinese medicine. The brain is deficient due to the loss of the marrow and the loss of the mental function. It is manifested as mental retardation, slow response, amnesia, etc. For treatment, the method of tonifying kidney, nourishing marrow and replenishing essence is used. In the invention, ginseng and astragalus root are the essential drugs for tonifying qi, prepared fleece-flower root and wolfberry fruit are the good products for tonifying kidney, jade wheat beard is the good product for regulating lipid and reducing blood sugar, leech is the essential drug for activating blood, the six drugs are used together for replenishing essence and benefiting marrow, the activities of SOD and catalase are improved, and Lipid Peroxide (LPO) and lipofuscin are reduced, thereby improving the learning ability, relieving the memory decline, improving the learning and memory disorders and finally achieving the purpose of improving the cognitive dysfunction symptoms of diabetes.
Description
Technical Field
The invention relates to a Chinese medicinal preparation, in particular to a Chinese medicinal composition for delaying cognitive dysfunction of diabetes.
Background
In recent years, cognitive dysfunction related to diabetes becomes a hot point of research, and belongs to one of the complications of the central nervous system of diabetes. Damage to the central nervous system from diabetes mainly affects the white matter of the cerebral cortex, which can cause damage to the structure and function of the brain tissue. The cognitive Dysfunction (DCI) of diabetes is mainly clinically manifested as learning and memory disorder, which is not easy to be found in the early stage of the disease course, and the patients can not take care of the life seriously in the later stage of the disease course, thus bringing heavy burden to the families and society of the patients. Therefore, early intervention is particularly important for cognitive dysfunction in diabetes.
The pathogenesis of diabetes cognitive dysfunction is closely related to hyperglycemia, the hyperglycemia has direct toxic effect on brain tissues, the hyperglycemia can increase blood brain barrier permeability to cause cell hypertonicity and edema, and then, accumulation of glycosylation end products (AGEs) directly damages neurons to cause mitochondrial dysfunction, induce oxidative stress, further activate apoptosis-related proteins to cause nerve cell apoptosis. Increased Receptor for AGE (RAGE) expression may increase the precipitation of a β in brain tissue. After the AGE is combined with the RAGE, the production of free radicals can be increased, the oxidative stress is promoted, the expression level of various cytokines is changed, and the cell function is further influenced. The above combined actions further initiate and accelerate arteriosclerosis, neuronal damage and cognitive dysfunction. At present, the treatment aiming at the cognitive dysfunction of diabetes mainly aims at controlling blood sugar, blood fat and blood pressure, improving insulin resistance, avoiding bad life style and the like, avoiding some risk factors, and no effective treatment medicine exists.
The traditional Chinese medicine is traditional medicine in China, has unexpected effects on diseases with unknown causes or poor treatment effect of western medicine, but has poor compliance of patients due to the fact that the traditional Chinese medicine is required to be decocted and is time-consuming and labor-consuming when being taken, and can not be taken on time, and finally the treatment effect is poor.
Disclosure of Invention
The invention takes the pathogenesis of the cognitive dysfunction of diabetes as the entry point, and prepares a traditional Chinese medicine prescription composition aiming at the damage of brain tissue structure and function caused by a series of oxidative stress reaction generated by hyperglycemia on the brain tissue, and the traditional Chinese medicine prescription composition is used for delaying the disease progress of the cognitive dysfunction of diabetes and improving the clinical manifestations of learning and memory disorders.
It is another object of the present invention to provide a process for the preparation of the above composition.
The technical scheme adopted by the invention is as follows: a Chinese medicinal composition for delaying diabetes cognitive dysfunction comprises Ginseng radix extract, radix astragali extract, Polygoni Multiflori radix extract, fructus Lycii extract, Leptoradix Seu caulis Erythrinae extract and Hirudo extract.
Preferably, the traditional Chinese medicine composition for delaying the cognitive dysfunction caused by diabetes comprises the following components in parts by weight: 20-30 parts of ginseng extract, 10-20 parts of astragalus extract, 30-40 parts of polygonum multiflorum extract, 20-30 parts of medlar extract, 20-30 parts of hordei yumai extract and 20-30 parts of leech extract.
In the traditional Chinese medicine composition for delaying the cognitive dysfunction of diabetes, the ginseng extract is ginsenoside.
In the traditional Chinese medicine composition for delaying the cognitive dysfunction of diabetes, the astragalus extract is astragaloside IV.
In the traditional Chinese medicine composition for delaying the cognitive dysfunction caused by diabetes, the prepared polygonum multiflorum extract is polygonum multiflorum polysaccharide.
In the traditional Chinese medicine composition for delaying the cognitive dysfunction of diabetes, the wolfberry fruit extract is wolfberry fruit polysaccharide.
In the traditional Chinese medicine composition for delaying the cognitive dysfunction caused by diabetes, the Leptoradix Seu folium Leptoradix Henryi extract is Leptoradix Seu folium Leptoradix Henri alcohol.
In the traditional Chinese medicine composition for delaying the cognitive dysfunction of diabetes, the leech extract is hirudin.
The preparation method for preparing the traditional Chinese medicine prescription composition sequentially comprises the following steps:
1. drying: the medicine is laid in a metal disc which is easy to conduct heat and dried.
2. Crushing: pulverizing the medicinal materials with universal pulverizer.
3. Starting a mother: dipping a little water in a dry bamboo plaque 1/4, uniformly coating the water on the plaque to wet the plaque as a water area, sieving a little medicinal powder on the wet plaque by a medicinal sieve without excessive water dripping, rotating the bamboo plaque by a double-hand-held plaque in a rolling motion to completely wet the medicinal powder in the water area, then lightly brushing the medicinal powder by a drying brush sequentially by a brush tip, rotating the bamboo plaque, moving all the wet fine particles to the other side of the dried bamboo plaque, brushing a little water on the water area of the bamboo plaque, moving the sticky powder particles to the water area, dipping all the water, brushing the medicinal powder by the brush, transferring to a dry place until the medicinal powder becomes dark, then spraying the medicinal powder, rolling all the wet particles with the medicinal powder, repeating the steps for a plurality of times until micro-dense pellets are formed, sieving the bamboo plaque is not sticky, and the pellets with uniform size are reserved.
4. Molding: the mother pills of the pills are gradually moistened by adding water and then the pills are gradually enlarged by adding the medicine powder. Putting the well-picked mother pills into a medicine plaque, adding proper water into a water area of the medicine plaque, shaking the pills to the water area in a clockwise manner, shaking continuously to enable the water to be uniformly scattered on the surfaces of the pills to enable the pills to be uniformly wet, after moisture is absorbed, rotating and shaking the pills to a dry area of the medicine plaque, observing whether the pills absorb sufficient moisture, and then adding proper amount of medicinal powder.
5. And (3) covering: selecting clear water to cover the noodles.
6. And (3) drying: opening a hot air circulation oven, filling the pills into the hot air circulation oven, and flatly paving the pills, wherein the thickness of the pills is not more than 2 cm. The oven was then turned off, the temperature was set at 60 degrees, and heating was started, turning the pellets over at intervals to avoid the pellets developing a sunny side. The temperature was then gradually increased to 80 ℃ until the end of drying. The oven was then turned off and the pellets were removed and allowed to cool.
7. Selecting pills: and removing unqualified pills in the pills by using the medicine sieve, and then sequentially subpackaging the qualified pills.
The invention has the beneficial effects that: the cognitive dysfunction of diabetes belongs to the category of dementia in traditional Chinese medicine. The brain is deficient due to the loss of the marrow and the loss of the mental function. It is manifested as mental retardation, slow response, amnesia, etc. For treatment, the method of tonifying kidney, nourishing marrow and replenishing essence is used. In the invention, ginseng and astragalus root are the essential drugs for tonifying qi, prepared fleece-flower root and wolfberry fruit are the good products for tonifying kidney, jade wheat beard is the good product for regulating lipid and reducing blood sugar, leech is the essential drug for activating blood, the six drugs are used together for replenishing essence and benefiting marrow, the activities of SOD and catalase are improved, and Lipid Peroxide (LPO) and lipofuscin are reduced, thereby improving the learning ability, relieving the memory decline, improving the learning and memory disorders and finally achieving the purpose of improving the cognitive dysfunction symptoms of diabetes.
Drawings
Figure 1 is the scoring of the rat search platform strategy.
Detailed Description
The invention is further illustrated by the following examples and comparative examples.
Example 1
Composition of Chinese medicine
A traditional Chinese medicine composition for delaying diabetes cognitive dysfunction comprises the following components in parts by weight: 25 parts of ginseng extract, 15 parts of astragalus extract, 35 parts of polygonum multiflorum extract, 25 parts of medlar extract, 25 parts of hordei yumai whisker extract and 25 parts of leech extract.
The Ginseng radix extract is ginsenoside. The radix astragali extract is astragaloside IV. The prepared polygonum multiflorum extract is polygonum multiflorum polysaccharide. The fructus Lycii extract is fructus Lycii polysaccharide. The described yumaixu extract is yumaixuenol. The leech extract is hirudin.
(II) preparation method
1. Drying: the medicine is laid in a metal disc which is easy to conduct heat and dried.
2. Crushing: pulverizing the medicinal materials with universal pulverizer.
3. Starting a mother: dipping a little water in a dry bamboo plaque 1/4, uniformly coating the water on the plaque to wet the plaque as a water area, sieving a little medicinal powder on the wet plaque by a medicinal sieve without excessive water dripping, rotating the bamboo plaque by a double-hand-held plaque in a rolling motion to completely wet the medicinal powder in the water area, then lightly brushing the medicinal powder by a drying brush sequentially by a brush tip, rotating the bamboo plaque, moving all the wet fine particles to the other side of the dried bamboo plaque, brushing a little water on the water area of the bamboo plaque, moving the sticky powder particles to the water area, dipping all the water, brushing the medicinal powder by the brush, transferring to a dry place until the medicinal powder becomes dark, then spraying the medicinal powder, rolling all the wet particles with the medicinal powder, repeating the steps for a plurality of times until micro-dense pellets are formed, sieving the bamboo plaque is not sticky, and the pellets with uniform size are reserved.
4. Molding: the mother pills of the pill are gradually moistened by adding water and then the powder is added to gradually enlarge the pill. Putting the well-picked mother pills into a medicine plaque, adding proper water into a water area of the medicine plaque, shaking the pills to the water area in a clockwise manner, shaking continuously to enable the water to be uniformly scattered on the surfaces of the pills to enable the pills to be uniformly wet, after moisture is absorbed, rotating and shaking the pills to a dry area of the medicine plaque, observing whether the pills absorb sufficient moisture, and then adding proper amount of medicinal powder.
5. And (3) covering: selecting clear water to cover the noodles.
6. And (3) drying: opening a hot air circulation oven, filling the pills into the hot air circulation oven, and flatly paving the pills, wherein the thickness of the pills is not more than 2 cm. The oven was then turned off, the temperature was set at 60 degrees, and heating was started, turning the pellets over at intervals to avoid the pellets developing a sunny side. The temperature was then gradually increased to 80 ℃ until the end of drying. The oven was then turned off and the pellets were removed and allowed to cool.
7. Selecting pills: and removing unqualified pills in the pills by using the medicine sieve, and then sequentially subpackaging the qualified pills.
(III) Effect test
40 SD rats were randomly divided into a blank control group, a model group, a low dose treatment group and a high dose treatment group, 10 rats per group. Model group, low dose treatment group and high dose treatment group 3 groups of SD rats 60 mg.kg-1Injecting Streptozotocin (STZ) into abdominal cavity, injecting sterile citric acid-sodium citrate buffer solution into blank control at one time according to the same volume, collecting blood in tail vein after 72h to determine fasting blood glucose, wherein the rat with blood glucose ratio greater than 16.7mmol/L is a diabetes model molding rat. Blank control group and model groupWithout any intervention. The low-dose treatment group and the high-dose treatment group were administered with low-dose and high-dose Chinese medicinal formulae, respectively, and gavage was performed. Each group of rats was periodically monitored for body weight and tail vein peripheral blood glucose and each group of rats was subjected to Morris water maze test at week 8 of the molding. The rats were placed in water for free swimming for 2 min 1 day afternoon before the experiment, and their swimming postures were observed and made familiar with the experimental environment. During learning, the rat is lightly put in water from any quadrant into the water, with the head facing the wall of the pool, and the water entry time and the incubation period of the animal are recorded. Each rat learned 1 time per day in each quadrant, setting the maximum swimming time to 120 s. The first 4 days are training hours and day 5 is the test day. After the experiment, the time required for the rat to search to reach the platform (escape latency) and the strategy for searching the platform (circle type, score 1, random type, score 2, curve type, score 3, straight line type, score 4) are recorded. After the Morris water maze test is finished, the weight of each group of rats is weighed, and the rats are given with 10% chloral hydrate solution according to the proportion of 3 mL-kg-1The abdominal cavity injection is used for anesthesia, the abdominal aorta of the rat is used for blood sampling, and the whole blood plasma is reserved for detecting the blood sugar and the glycosylated hemoglobin. Cutting off the head after blood sampling, taking out the whole brain, and weighing.
The experimental results are as follows:
1. the results of the tests of brain weight, body weight, blood glucose and glycated hemoglobin (HbAlc) of the rats in each group are shown in Table 1, and compared with the rats in the blank control group, the rats in the model group have obvious polydipsia, polyphagia, polyuria, sparse hair, dull color, obviously reduced night activity and slow weight increase. The brain weight and the body weight of the rats in the model group are obviously reduced (P <0.05) compared with those in the blank control group, and the brain weight and the body weight of the rats in the low-dose and high-dose treatment groups are increased (P <0.05) compared with those in the model group, and the differences have statistical significance. The blood sugar of the rats in the model group is obviously increased (P <0.05) compared with that of the blank control group, and the blood sugar of the rats in the low-dose and high-dose treatment groups is reduced (P <0.05) compared with that of the comparison group in the model group, and the differences have statistical significance. The SOD value of model rats is obviously reduced compared with that of a blank control group (P <0.05), and the SOD value of serum of rats in low-dose and high-dose treatment groups is increased compared with that of the model groups (P < 0.05). The above experimental results suggest that the Chinese medicinal formula of the invention can improve the symptoms of diabetes with more than three and one less, thereby reducing blood sugar, improving the reduction of brain weight and improving brain atrophy. The SOD value of serum can reflect the degree of oxidative stress of organisms, and the SOD values of two groups of rats in a treatment group are increased according to the experimental results, which prompts that the invention can relieve the oxidative stress of diabetic rats.
TABLE 1 rat brain weight, body weight, blood glucose, SOD
2. Morris Water maze test results
(1) Comparison of results of escape latency of two groups of rats in water maze experiment
The rats in each group swim freely 1 day before the experiment, and the swimming postures of the rats are observed to be abnormal, which indicates that the locomotivity of the rats in each group is normal. However, in the subsequent experiments, the model group rats had an increased wandering distance and a significantly increased escape latency (P <0.01) compared to the blank control group, and the low-dose and high-dose treatment group rats had a significantly decreased escape latency (P <0.05) compared to the model group, as shown in Table 2.
TABLE 2 comparison of escape latency results from water maze experiments in various groups of rats
(2) Scoring of search platform strategy for groups of rats on day 5
The scoring of the rat search platform strategy of each group at day 5 is shown in fig. 1, the scores of the model group rats are significantly reduced compared with the blank control group, the scores of the rats of the low-dose and high-dose treatment groups are increased compared with the model group, and the difference is statistically significant (P < 0.05).
The water maze is an effective experiment for evaluating the learning and memory abilities of rats, and the experimental results suggest that the rats in a model group have obvious learning and memory abilities disorder, and the rats in a low-dose and high-dose treatment group have obviously improved learning and memory abilities after treatment, so that the traditional Chinese medicine formula can improve the clinical symptoms of diabetic cognitive dysfunction.
Claims (1)
1. A traditional Chinese medicine composition for delaying diabetes cognitive dysfunction is characterized by comprising the following components in parts by weight: 25 parts of ginsenoside extracted from ginseng, 15 parts of astragaloside extracted from astragalus, 35 parts of polygonum multiflorum polysaccharide extracted from polygonum multiflorum, 25 parts of lycium barbarum polysaccharide extracted from medlar, 25 parts of yumaixu alcohol extracted from yumaixu and 25 parts of hirudin extracted from leech;
the preparation method of the traditional Chinese medicine composition comprises the following steps:
1) drying: laying the raw material medicines in a metal disc for drying;
2) crushing: crushing the raw material medicaments by a crusher;
3) starting a mother: dipping a little water in a brush at 1/4 position of a dry bamboo plaque to uniformly coat the plaque surface to be a water area, sieving a little raw material medicinal powder on the wet plaque surface by a medicinal sieve, rotating the bamboo plaque by a double-hand held plaque in a rolling motion to completely wet the medicinal powder in the water area, then lightly brushing the medicinal powder by a brush tip in sequence by a drying brush, rotating the bamboo plaque, completely moving the wetted fine particles to the other side of the bamboo plaque, brushing a little water on the water area of the bamboo plaque, moving the sticky powder particles to the water area, completely dipping the water, brushing the medicinal powder by the brush, then rotating to the dry position until the medicinal powder becomes dark, then spraying the medicinal powder, completely rolling the wet particles with the medicinal powder, repeating the steps for a plurality of times until micro-dense pellets are formed, sieving the bamboo plaque is not sticky, and pills with uniform size are reserved;
4) molding: adding water to wet a mother pill of the pill step by step, adding medicine powder to increase the pill gradually, putting the well-lifted mother pill into a medicine plaque, adding proper water into a water area of the medicine plaque, shaking the pill to the water area in a clockwise manner, shaking continuously to enable the water to be uniformly sprayed on the surface of the pill to enable the pill to be uniformly wet, sucking the water, then rotating and shaking the pill to a dry area of the medicine plaque, observing whether the pill absorbs enough water or not, and then adding proper amount of medicine powder;
5) and (3) covering: selecting clear water to cover the noodles;
6) and (3) drying: opening a hot air circulation oven, filling the pills into the hot air circulation oven, flatly paving the pills, setting the temperature to be 60 ℃, then starting heating, turning the pills once at intervals to avoid the pills from generating sunny and shady surfaces, and then gradually raising the temperature to 80 ℃ until the drying is finished.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810004308.1A CN108066647B (en) | 2018-01-03 | 2018-01-03 | Traditional Chinese medicine composition for delaying diabetes cognitive dysfunction and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810004308.1A CN108066647B (en) | 2018-01-03 | 2018-01-03 | Traditional Chinese medicine composition for delaying diabetes cognitive dysfunction and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108066647A CN108066647A (en) | 2018-05-25 |
| CN108066647B true CN108066647B (en) | 2021-06-18 |
Family
ID=62156296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810004308.1A Active CN108066647B (en) | 2018-01-03 | 2018-01-03 | Traditional Chinese medicine composition for delaying diabetes cognitive dysfunction and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108066647B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816234A (en) * | 2014-02-13 | 2014-05-28 | 四川省中医药科学院 | Pharmaceutical composition capable of improving cognitive ability, preparation method and applications thereof |
| CN106309727A (en) * | 2016-09-19 | 2017-01-11 | 北京大学第医院 | Traditional Chinese medicine composition for preventing and treating cognition impairment of kidney deficiency and blood stasis type 2-type diabetes mellitus |
-
2018
- 2018-01-03 CN CN201810004308.1A patent/CN108066647B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103816234A (en) * | 2014-02-13 | 2014-05-28 | 四川省中医药科学院 | Pharmaceutical composition capable of improving cognitive ability, preparation method and applications thereof |
| CN106309727A (en) * | 2016-09-19 | 2017-01-11 | 北京大学第医院 | Traditional Chinese medicine composition for preventing and treating cognition impairment of kidney deficiency and blood stasis type 2-type diabetes mellitus |
Non-Patent Citations (1)
| Title |
|---|
| 糖尿病认知障碍的中药研究进展;李莹等;《食品与药品》;20160430;第18卷(第4期);第293页右栏第1段,第294页右栏第1段,第293页左栏第1段和第294页左栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108066647A (en) | 2018-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1043010C (en) | Spot curing and beautifying preparation | |
| CN104383296B (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof | |
| CN103055239B (en) | Traditional Chinese medicine for beautifying face and removing freckles and preparation method thereof | |
| CN106539083A (en) | It is a kind of to be used to prevent and treat diabetic retinopathy, alleviate asthenopic compositionss | |
| CN104107269A (en) | Functional blood sugar-reduction health product and preparation method thereof | |
| CN112915181B (en) | Qi-tonifying and vitality-restoring cream formula and application thereof | |
| CN108066647B (en) | Traditional Chinese medicine composition for delaying diabetes cognitive dysfunction and preparation method thereof | |
| CN110694013A (en) | Pressed candy for relieving alopecia and preparation process thereof | |
| CN106421590A (en) | Pharmaceutical preparation for treating color mottles and application of pharmaceutical preparation | |
| CN106361878A (en) | Hair blackening and growing pill and preparation method thereof | |
| CN105412604A (en) | Traditional Chinese medicine composition for auxiliary treatment of diabetes and preparation method of traditional Chinese medicine composition | |
| CN114209758A (en) | Traditional Chinese medicine compound composition capable of maintaining blood sugar health level and preparation method and application thereof | |
| CN101036749A (en) | External emplastrum for treating asthenic fever for children and the preparing method | |
| CN108403869B (en) | Traditional Chinese medicine composition for removing chloasma and preparation method thereof | |
| CN104173699B (en) | A kind of chewable tablets of anti-treating dental ulcer and preparation method thereof | |
| CN112704699A (en) | Traditional Chinese medicine composition for treating climacteric syndrome and application thereof | |
| CN114272295A (en) | Traditional Chinese medicine composition for treating diabetic acromelic gangrene | |
| CN105381201A (en) | Preparation method for traditional Chinese medicine used for diabetes | |
| CN107875288A (en) | Preparation method with promoting blood circulation, the Chinese medicine composition of beauty functions and its granule | |
| CN114848554B (en) | Plant compound capable of preventing hair loss and growing hair and preparation method thereof | |
| CN108671149B (en) | Traditional Chinese medicine composition for treating liver diseases and preparation thereof | |
| CN110585329A (en) | Pharmaceutical composition with blood sugar reducing effect and preparation method and application thereof | |
| CN114558051B (en) | Chinese medicinal composition for treating diabetes and preparation method thereof | |
| CN114588228B (en) | Composition for treating type 2 diabetes | |
| CN112675264B (en) | Composition for treating psoriasis, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180815 Address after: 110000 Surabaya street, Hunnan District, Shenyang, Liaoning 66 Applicant after: Shenyang eye Industrial Technology Research Institute Co., Ltd. Applicant after: HE UNIVERSITY Address before: 110163 Surabaya street, Hunnan District, Shenyang, Liaoning 66 Applicant before: HE UNIVERSITY |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |